Previous 10 | Next 10 |
Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. Jointech, a Hangzhou medical device company, has raised $62 million over the last 15 months to support its orthopedic surgery ...
The China National Medical Products Administration ((NMPA)) has approved BeiGene's (BGNE) anti-PD-1 antibody tislelizumab for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer ((NSCLC)) and granted conditional approval for the treatment of patients wit...
Tislelizumab is approved for the first-line treatment of advanced non-squamous non-small cell lung cancer following the previously approved squamous histology Tislelizumab receives its first approval in liver cancer in previously treated hepatocellular carcinoma Be...
Shanghai's Zai Lab announced a four-drug immuno-oncology deal with MacroGenics worth over $1.4 billion. Beijing's LinkDoc Technology, an AI-driven healthcare company based on cancer patient data, filed to IPO on the NASDAQ exchange. Suzhou Innovent Bio has dosed the first person i...
BeiGene (BGNE) announces that BRUKINSA (zanubrutinib) has received conditional approval from the China National Medical Products Administration ((NMPA)) for the treatment of adult patients with Waldenström’s macroglobulinemia ((WM)) who have received at least one prior t...
Third approval for BRUKINSA in China and second approval in WM worldwide BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA ® (zanubrut...
The first patient has been dosed in BeiGene's (BGNE) Phase 3 AdvanTIG-302 trial of anti-TIGIT antibody ociperlimab (BGB-A1217) in combination with anti-PD-1 antibody tislelizumab, for the first-line treatment of patients with non-small cell lung cancer ((NSCLC)) whose tumors exhibit high PD-L...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient was dosed in the global Phase 3 AdvanTIG-302 trial of BeiGene’s investigational anti-TIGI...
Asieris Pharmaceuticals (Asieris) announces that the FDA has approved the IND application of oral APL-1202 in combination with BeiGene's (BGNE) tislelizumab as neoadjuvant therapy in patients with muscle invasive bladder cancer ((MIBC)).Asieris will accelerate the initiation of the clinical t...
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. Beijing's BeiGene presented positive interim results from Phase III trial that compared its BTK candidate to AbbVie's Imbruv...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...